Newsroom
Biodelphis Therapeutics receives CHF 150,000 from Venture Kick to advance targeted therapies for difficult-to-treat cancers
22.05.2026
The EPFL spin-off Biodelphis Therapeutics has obtained CHF 150,000 from Venture Kick to develop a new generation of targeted therapies for cancers that do not respond well to existing treatments. The biotech startup aims to improve treatmen ... mehr
HAYA Therapeutics starts clinical trial for heart disease therapy
20.05.2026
Swiss biotech company HAYA Therapeutics has reached a new milestone as it officially entered the clinical stage with the dosing of the first cohort in its Phase 1 trial for HTX-001, an investigational therapy targeting cardiac fibrosis in p ... mehr
Neurosoft Bioelectronics raises USD 7.5M Seed round for brain-computer interfaces
20.05.2026
Swiss neurotechnology company Neurosoft Bioelectronics has closed a USD 7.5 million oversubscribed Seed financing round to accelerate the development of its minimally invasive brain-computer interface (BCI) platform and expand clinical tria ... mehr
Newsletter Archiv
Spring momentum across Swiss startups 🌱
A record 2025, and kicking bigger in 2026! 🚀
Kicking Finish, Bold Outlook✨
Medienmitteilungen
Presseschau
1000 Unternehmen mit Venture Kick gegründet
Medienanfragen
Für Presseanfragen, schreiben Sie bitte unserem Kommunikationsteam. Falls Sie generelle Fragen zu Venture Kick haben, gehen Sie bitte auf unsere Kontaktseite.
Erfahren Sie mehr über Venture Kick oder laden Sie sich unseren letzten Jahresbericht herunter für detaillierte Informationen.